Shares of Hims & Hers Health Inc. experienced a notable rally, climbing approximately 6.4% to trade near $20. This upward movement was driven by two significant developments: potential regulatory changes from the U.S. Food and Drug Administration (FDA) and the formal launch of a key collaboration with pharmaceutical giant Novo Nordisk.
Potential FDA Policy Reversal on Peptides
Market observers point to Washington as the source of the more impactful catalyst. Reports indicate the FDA is considering reversing a ban imposed in 2023 on 14 specific peptides. The public endorsement of these substances’ clinical benefits by HHS Secretary RFK Jr. is viewed as a positive signal for the telehealth and wellness sector.
A policy shift would hold particular significance for Hims & Hers. The company strategically acquired a specialized peptide manufacturing facility in California back in February 2025. Should the regulatory restrictions be lifted, the company would be positioned to seamlessly incorporate these treatments into its platform of personalized medication offerings.
Formal Launch of Novo Nordisk Collaboration
Concurrently, the company has officially commenced its previously announced partnership with Novo Nordisk. Through a new membership model, patients can now access the GLP-1 medications Wegovy and Ozempic. The program is priced at $39 for the initial month, followed by a $149 monthly membership fee, plus a minimum of $149 for the prescribed medications themselves.
Should investors sell immediately? Or is it worth buying Hims & Hers?
This move strategically positions Hims & Hers in the rapidly expanding digital obesity treatment market. Industry forecasts project this sector could grow to around $247 billion by 2030, expanding at a compound annual growth rate of 25.6%. The partnership allows Hims & Hers to establish an early foothold with branded GLP-1 therapies.
Market Valuation and Analyst Perspectives
Despite the day’s gains, the stock remains down roughly 39% since the start of the year. Its forward price-to-sales multiple of 1.5x sits notably below the industry average of 3.2x, suggesting the market may not be fully pricing in the company’s growth narrative.
Analyst sentiment remains cautious. TD Cowen adjusted its price target downward from $25 to $23 while maintaining a “Hold” rating. Bank of America also maintains a neutral stance, noting that the pricing for the new GLP-1 program slightly exceeds initial market expectations.
Another factor in the trading activity is the significant short interest, which stands at approximately 44% of the float. The high trading volume of nearly 15 million shares today suggests the rally was likely amplified, at least in part, by short sellers covering their positions. Looking ahead, the consensus analyst estimate for full-year 2026 revenue is $2.73 billion, representing a 16.4% increase over projected 2025 figures.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from April 1 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 1.
Hims & Hers: Buy or sell? Read more here...
